{"filing":{"accession_number":"0001438533-26-000048","cik":"0001438533","ticker":"TVTX","company_name":"Travere Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-16","report_date":null,"primary_document":"tvtx-20260612.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1438533/000143853326000048/tvtx-20260612.htm"},"events":[{"id":11349,"run_id":9965,"accession_number":"0001438533-26-000048","anchor_item_number":"5.02","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.75,"summary":"Dr. William Rote, Chief Research Officer, provided notice of his intention to retire effective February 17, 2027. While the filing also discloses Dr. Jula Inrig's appointment as Executive Vice President, Head of R\u0026D and Chief Medical Officer, the principal disclosed action centers on Dr. Rote's departure from a senior executive role overseeing research operations. The departure of a C-suite officer responsible for research is material to investors assessing the company's leadership continuity and R\u0026D capabilities.","company_name":"Travere Therapeutics, Inc.","ticker":"TVTX","filing_date":"2026-06-16","form":"8-K","submitted_at":null,"items":[{"id":7916,"accession_number":"0001438533-26-000048","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"Dr. William Rote, Chief Research Officer, provided notice of his intention to retire effective February 17, 2027. While the filing also discloses Dr. Jula Inrig's appointment as Executive Vice President, Head of R\u0026D and Chief Medical Officer, the principal disclosed action centers on Dr. Rote's departure from a senior executive role overseeing research operations. The departure of a C-suite officer responsible for research is material to investors assessing the company's leadership continuity and R\u0026D capabilities.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-16T20:36:12.095359+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":7916,"accession_number":"0001438533-26-000048","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"Dr. William Rote, Chief Research Officer, provided notice of his intention to retire effective February 17, 2027. While the filing also discloses Dr. Jula Inrig's appointment as Executive Vice President, Head of R\u0026D and Chief Medical Officer, the principal disclosed action centers on Dr. Rote's departure from a senior executive role overseeing research operations. The departure of a C-suite officer responsible for research is material to investors assessing the company's leadership continuity and R\u0026D capabilities.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-16T20:36:12.095359+00:00","company_name":"Travere Therapeutics, Inc.","ticker":"TVTX","filing_date":"2026-06-16"}]}